Session

Back to Programme Overview

Immune therapy and targeted therapy in urothelial cancer

Poster Session 73

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chairs:
     Y. Allory, Creteil (FR)
     A. Sato, Tokorozawa (JP)
     A. Vlahou, Athens (GR)
  • Aims and objectives of this session

    Not all patients respond to BCG therapy for urothelium tumours. Immunological mechanisms relevant to a possible improvement of BCG treatment will be discussed in this session. In addition, novel functions of growth factors which are highly expressed in bladder cancer will be presented.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
964
Immune responsiveness to tuberculin in vitro may predict clinical outcome of intravesical BCG immunotherapy in bladder cancer

By: Jallad S.1, Thomas D.2, Thomas P.3, Newport M.4, Kern F.4

Institutes: 1Brighton and Sussex Medical School, Dept. of Urology, Brighton, United Kingdom, 2Brighton and Sussex Medical School, Division of Medicine, Brighton, United Kingdom, 3Brighton and Sussex University Hospitals, Dept. of Urology, Brighton, United Kingdom, 4Brighton and Sussex University Hospitals, Division of Medicine, Brighton, United Kingdom

965
Evaluation of pro- and anti-tumor effect induced by three colony-stimulating factors, G-CSF/GM-CSF/M-CSF using a human bladder cancer xenograft model: Is G-CSF a friend of cancer cells?

By: Hori S., Miyake M., Tatsumi Y., Morizawa Y., Nakai Y., Goto D., Onishi K., Iida K., Onishi S., Tanaka N., Fujimoto K.

Institutes: Nara Medical University, Dept. of Urology, Kashihara, Japan

* 966
Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells

By: Ferreira-Teixeira M.2, Parada B.1, Paiva-Oliveira D.2, Alves V.3, Sousa V.4, Chijioke O.5, Münz C.5, Reis F.6, Rodrigues-Santos P.7, Gomes C.6

Institutes: 1Coimbra University Hospital (CHUC), Urology and Renal Transplantation, Coimbra, Portugal, 2University of Coimbra – Faculty of Medicine, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, 3University of Coimbra – Faculty of Medicine, Institute of Immunology, Coimbra, Portugal, 4University of Coimbra – Faculty of Medicine, Institute of Anatomical and Molecular Pathology, Coimbra, Portugal, 5University of Zurich, Viral Immunobiology, Institute of Experimental Immunology, Zurich, Switzerland, 6University of Coimbra – Faculty of Medicine, Laboratory of Pharmacology and Experimental Therapeutics, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, 7University of Coimbra – Center For Neurosciences and Cell Biology (CNC), Immunology and Oncology Laboratory, Coimbra, Portugal

968
IFN alpha modulates the response to BCG immunotherapy in bladder cancer patients with specific CTLA4 and CD28 single nucleotide polymorphisms

By: Esuvaranathan K., Rahmat J., Tham S.M., Lim Y.K., Sng J.H., Raman L., Ma Z.M., Chan Y.H., Tsang W.C., Chiong E., Mahendran R.

Institutes: National University Singapore, Dept of Urology, Singapore, Singapore

969
Inhibition of LIM-SH3 domain protein 1 (LASP1) augments the anti-cancer effect of cisplatin in bladder cancer

By: Dejima T.1, Takeuchi A.1, Shiota M.1, Black P.2, Eto M.1, Naito S.1, Gleave M.2, Ong C.2

Institutes: 1Kyusyu University, Dept. of Urology, Fukuoka, Japan, 2The Vancouver Prostate Centre, Dept. of Urologic Sciences, University of British Columbia, Vancouver, Canada

970
HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy

By: Shintani T., Daizumoto K., Fukawa T., Nakatsuji H., Fukumori T., Takahashi M., Kanayama H.

Institutes: Institute of Biomedical Sciences, Tokushima University Graduate School, Dept. of Urology, Tokushima, Japan

971
The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine

By: Isono M.1, Sato A.1, Asano T.1, Okubo K.1, Hoffmann M.2, Schulz W.2, Asano T.1

Institutes: 1National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, 2Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

972
T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+

By: Hayashi T.1, Oo H.2, Jäger W.2, Kobatake K.1, Goriki A.2, Seiler R.2, Todenhöfer T.2, Li N.2, Fazli L.2, Matsubara A.1, Black P.2

Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

973
Pathological significance and prognostic roles of c-Fes expression in bladder cancer differ depending on the grade

By: Asai A., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Ohba K., Sakai H.

Institutes: Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan

974
Reduced expressions of 4N1K-peptide derived from thrombospondin-2 is associated with malignant aggressiveness and prognosis in bladder cancer

By: Mochizuki Y.1, Miyata Y.1, Yasuda T.1, Nakamura Y.1, Matsuo T.1, Ohba K.1, Furusato B.2, Fukuoka J.2, Sakai H.1

Institutes: 1Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, 2Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

975
Compound A inhibits urothelial tumorigenesis via both glucocorticoid receptor and androgen receptor pathways

By: Ide H.2, Inoue S.3, Zheng Y.2, Kashiwagi E.4, Kawahara T.5, Miyamoto H.1

Institutes: 1University of Rochester, Dept. of Pathology, Urology and Oncology, Rochester, United States of America, 2Johns Hopkins University, Dept. of Pathology and Urology, Baltimore, United States of America, 3University of Rochester, Dept. of Pathology and Oncology, Rochester, United States of America, 4Kyushu University, Dept. of Urology, Fukuoka, Japan, 5Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan

New targets in urothelial cancer
 Y. Allory, Creteil (FR)